Market Overview:
The global hyperlipidemia drugs market reached a value of US$ 21.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 24.8 Billion by 2027, exhibiting a CAGR of 2.17% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Hyperlipidemia, or high cholesterol, refers to a medical ailment characterized by high levels of fats in the bloodstream. It is the abnormal elevation of lipids and/or lipoprotein levels that can lead to stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension, and cardiovascular diseases. It is usually caused by genetic factors, unhealthy lifestyles and inadequate diet. Some of the commonly used hyperlipidemia drugs include statins, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, bile acid sequestrants, fibric acid derivatives or fibrates and combination and miscellaneous antihyperlipidemic agents. These drugs reduce cholesterol production levels in the liver while further removing it from the bloodstream.
The increasing prevalence of hyperlipidemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to high levels of cholesterol and cardiovascular diseases, is also driving the market growth. In line with this, rising health consciousness among the masses and growing awareness regarding the available treatment alternatives for hypercholesterolemia is also favoring the market growth. Additionally, various technological advancements, such as the development of novel drug classes with enhanced efficacy, are acting as other growth-inducing factors. These drugs offer improved endothelial function and stability of atherosclerotic plaques and cause minimal inflammation and damage to the cells. Other factors, including the extensive research and development (R&D) activities in the field of biomedical sciences, along with overall improvements in the healthcare infrastructure across the globe, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hyperlipidemia drugs market report, along with forecasts for growth at the global and regional level from 2022-2027. Our report has categorized the market based on drug type and end-user
Breakup by Drug Type:
- Statins
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- PCSK9 Inhibitors
- Others
Breakup by End User:
Breakup by Region:
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022-2027 |
| Units |
US$ Billion |
| Segment Coverage |
Drug Type, End User, Region |
| Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered |
Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc. and Sanofi S.A. |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hyperlipidemia Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Type
6.1 Statins
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Bile Acid Sequestrants
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Cholesterol Absorption Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 PCSK9 Inhibitors
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by End User
7.1 Hospitals
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Clinics
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Amgen Inc.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 AstraZeneca Plc
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 Daiichi Sankyo Company Limited
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 Eli Lilly and Company
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 Esperion Therapeutics Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.6 GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Immuron Limited
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.8 Ionis Pharmaceuticals Inc.
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.8.4 SWOT Analysis
13.3.9 Merck & Co. Inc.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
13.3.10 Pfizer Inc.
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financials
13.3.10.4 SWOT Analysis
13.3.11 Sanofi S.A.
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio
13.3.11.3 Financials
13.3.11.4 SWOT Analysis
List of Figures
Figure 1: Global: Hyperlipidemia Drugs Market: Major Drivers and Challenges
Figure 2: Global: Hyperlipidemia Drugs Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Hyperlipidemia Drugs Market: Breakup by Drug Type (in %), 2021
Figure 4: Global: Hyperlipidemia Drugs Market: Breakup by End User (in %), 2021
Figure 5: Global: Hyperlipidemia Drugs Market: Breakup by Region (in %), 2021
Figure 6: Global: Hyperlipidemia Drugs Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 7: Global: Hyperlipidemia Drugs (Statins) Market: Sales Value (in Million US$), 2016 & 2021
Figure 8: Global: Hyperlipidemia Drugs (Statins) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 9: Global: Hyperlipidemia Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Hyperlipidemia Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Hyperlipidemia Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Hyperlipidemia Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Hyperlipidemia Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Hyperlipidemia Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Hyperlipidemia Drugs (Other Drug Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Hyperlipidemia Drugs (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Hyperlipidemia Drugs (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Hyperlipidemia Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Hyperlipidemia Drugs (Clinics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Hyperlipidemia Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Hyperlipidemia Drugs (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Hyperlipidemia Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: North America: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: North America: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: United States: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: United States: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Canada: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Canada: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Asia Pacific: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Asia Pacific: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: China: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: China: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Japan: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Japan: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: India: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: India: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: South Korea: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: South Korea: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Australia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Australia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Indonesia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: Indonesia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Europe: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Europe: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: Germany: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: Germany: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: France: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: France: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: United Kingdom: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: United Kingdom: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: Italy: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: Italy: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: Spain: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: Spain: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Russia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Russia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Latin America: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Latin America: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Brazil: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Brazil: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Mexico: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Mexico: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Middle East and Africa: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Middle East and Africa: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Global: Hyperlipidemia Drugs Industry: SWOT Analysis
Figure 72: Global: Hyperlipidemia Drugs Industry: Value Chain Analysis
Figure 73: Global: Hyperlipidemia Drugs Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Global: Hyperlipidemia Drugs Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Hyperlipidemia Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2022-2027
Table 3: Global: Hyperlipidemia Drugs Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 4: Global: Hyperlipidemia Drugs Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 5: Global: Hyperlipidemia Drugs Market Structure
Table 6: Global: Hyperlipidemia Drugs Market: Key Player